Brain and behavior · 2025
Tenecteplase for Ischemic Stroke due to Large Vessel Occlusion at 4.5 to 24 Hours: A Meta-Analysis of Randomized Controlled Trials.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Shuangzhe, Wang Liyuan, Cao Zhixin, Hao Manjun, Wu Na, Shen Kejia, Tang Yizhe, Zhang Yige, Ma Yujie, Li Zhixin, Xiong Yunyun
Аннотация
BACKGROUND: Whether to use tenecteplase for acute ischemic stroke patients in the extended window has so far been little studied.
METHODS: In this meta-analysis, we included all the randomized controlled trials comparing tenecteplase with control at 4.5 to 24 h after the last known well of acute ischemic stroke with large vessel occlusion. A systematic search was performed in PubMed, Web of Science, Embase, and Cochrane Central Register of Controlled Trials databases, up to 12th June, 2024. Our primary outcome was an excellent functional outcome with a modified Rankin scale score (mRS) of 0-1 at 90 days. Our safety outcomes included mRS 5-6 at 90 days, mortality within 90 days, symptomatic intracranial hemorrhage and parenchymal hematoma Type 2.
RESULTS: Ultimately, three studies involving 1198 patients were included in the pooled analysis, where tenecteplase exhibited a higher rate of mRS 0-1 at 90 days (OR, 1.36; 95%CI, 1.07-1.75; p = 0.01) and recanalization (OR, 3.30; 95%CI, 1.59-6.84; p = 0.001). For other outcomes, no significant differences were found between groups.
CONCLUSIONS: This meta-analysis of randomized controlled trials manifested that tenecteplase within a 4.5- to 24-h time window of large vessel occlusion stroke was superior to control for an excellent functional outcome (mRS 0-1) without safety concerns.
METHODS: In this meta-analysis, we included all the randomized controlled trials comparing tenecteplase with control at 4.5 to 24 h after the last known well of acute ischemic stroke with large vessel occlusion. A systematic search was performed in PubMed, Web of Science, Embase, and Cochrane Central Register of Controlled Trials databases, up to 12th June, 2024. Our primary outcome was an excellent functional outcome with a modified Rankin scale score (mRS) of 0-1 at 90 days. Our safety outcomes included mRS 5-6 at 90 days, mortality within 90 days, symptomatic intracranial hemorrhage and parenchymal hematoma Type 2.
RESULTS: Ultimately, three studies involving 1198 patients were included in the pooled analysis, where tenecteplase exhibited a higher rate of mRS 0-1 at 90 days (OR, 1.36; 95%CI, 1.07-1.75; p = 0.01) and recanalization (OR, 3.30; 95%CI, 1.59-6.84; p = 0.001). For other outcomes, no significant differences were found between groups.
CONCLUSIONS: This meta-analysis of randomized controlled trials manifested that tenecteplase within a 4.5- to 24-h time window of large vessel occlusion stroke was superior to control for an excellent functional outcome (mRS 0-1) without safety concerns.